3 In Dahl salt-sensitive (S) rats, both enhanced Na + entry from the blood into the cerebrospinal fluid (CSF) and enhanced neuronal excitatory responses to Na + contribute to saltinduced sympathetic hyperactivity and hypertension (17, 19). In Dahl S on high salt, enhanced Na Microinjection of ouabain into the PVN causes dose-related increases in BP and HR, which can be prevented by an AT 1 receptor blocker (7). Thus, EO may inhibit Na SIK1 has also been identified in rat brain, and SIK1 mRNA increases up to 8 fold in the hippocampus and cortex following depolarization (6). We hypothesized that the SIK1- In the present study we examined whether SIK1 in the brain contributes to: 1) increases in Na + entry into CSF and in hypothalamic aldosterone in Dahl S rats on high salt; and 2) excitatory BP, HR and sympatho-excitatory responses to CSF [Na + ]. To assess the role of SIK1, we employed central administration of staurosporine. Staurosporine inhibits SIK1 activity at 5-10 nM (2.4-4.7 ng/ml, with MW=467) in vitro (22, 32), and at higher concentrations inhibits other kinases, eg. protein kinase C (PKC) with IC 50 of ~50 nM (2).
Microinjection of ouabain into the PVN causes dose-related increases in BP and HR, which can be prevented by an AT 1 receptor blocker (7) . Thus, EO may inhibit Na SIK1 has also been identified in rat brain, and SIK1 mRNA increases up to 8 fold in the hippocampus and cortex following depolarization (6) . We hypothesized that the SIK1- In the present study we examined whether SIK1 in the brain contributes to: 1) increases in Na + entry into CSF and in hypothalamic aldosterone in Dahl S rats on high salt; and 2) excitatory BP, HR and sympatho-excitatory responses to CSF [Na + ]. To assess the role of SIK1, we employed central administration of staurosporine. Staurosporine inhibits SIK1 activity at 5-10 nM (2.4-4.7 ng/ml, with MW=467) in vitro (22, 32), and at higher concentrations inhibits other kinases, eg. protein kinase C (PKC) with IC 50 of ~50 nM (2).
We assessed: 1) SIK protein and activity in hypothalamic tissue of Dahl S and saltresistant consomic SS.BN13 rats, and the concentrations of staurosporine needed to inhibit SIK1 activity; 2) effects of icv staurosporine on excitatory BP, HR and renal sympathetic nerve activity (RSNA) responses to icv infusion of Na + -rich aCSF in Dahl S, SS.BN13 and Wistar rats; 3) effects of chronic icv infusion of staurosporine on CSF [Na + ], resting BP and HR, and hypothalamic aldosterone and corticosterone content in Dahl S and SS.BN13 rats on high salt for 2 weeks; and 4) as "control" studies, effects of icv staurosporine on responses to icv Ang II and carbachol, and of the specific PKC inhibitor GF109203X on pressor responses to icv Na + -rich aCSF and icv Ang II..
Methods
Five to six week old male Dahl S rats (SS/Mcw) and salt-resistant consomic (SS.BN13) rats, and Wistar rats were purchased from Charles River, Montreal, Canada. SS.BN13 rats show functional and histological responses to high salt, which are similar to normotensive strains (4) , and are used as salt-resistant control for Dahl S rats (4, 11) . The animals were housed on a 12-hour light/dark cycle and fed a standard commercial rat chow with regular salt (101 µmol Na 
Effects of icv injection of staurosporine on responses to acute increases in CSF [Na

+
]
Effects on responses of BP, HR and renal sympathetic nerve activity (RSNA): Dahl S and SS.BN13 and Wistar rats (2 groups/strain, n=5-8/group) remained on regular salt intake.
Under isoflurane anesthesia a 23 gauge stainless steel cannula was placed just above the right lateral cerebro-ventricle as a guide cannula and fixed on the skull with dental cement (19). At least 5 days following the head surgery, the rats were anesthetized with isoflurane and the right femoral artery and vein were cannulated with PE10/PE50 tubings, which were tunnelled to the back of the neck. Through a flank incision, a pair of silver electrodes was then placed around and fixed to the left renal nerve with silicone rubber (Wacker Sil-Gel, 604 A B) and exteriorized as described previously (19).
At least 4 hours after recovery from the anesthesia in the original cage, the intra-arterial catheter was connected to a transducer to record BP and HR with a Grass polygraph (19).
The electrodes were connected to a high-impedance probe, and the electrical signals were amplified 20,000-50,000 times by a band-pass amplifier (Grass P511, Grass echnologies/Astro-Med Inc.) with a high-and low-frequency cutoff of 1000 and 30 Hz, respectively. The filtered signals were channeled to a rectifying voltage integrator (Grass 7P10) and recorded through the Grass polygraph. The RSNA signal (in mV), together with BP and HR, were also fed into an on-line computer with a Grass data acquisition and analysis program (Polyview 2.0). The signal noise for RSNA was determined after the rat had been killed at the end of the study, and subtracted from the total activity (19).
After a 30 min rest, baseline MAP, HR and RSNA were recorded in unrestrained animals for 10 min. A 26-gauge stainless steel needle was then inserted into the guide cannula so that its tip protruded into the lateral cerebro-ventricle. Via a PE tubing, the other end of the needle was connected to a 500 μl Hamilton micro-syringe, which was mounted on a Sage 355 infusion pump for icv infusion. Following a 20 min rest, Na GF109203X is a highly selective, cell-permeable PKC inhibitor with a similar structure to staurosporine. In vitro, the effective concentration of GF109203X is 1 μM (34) or 0.4 μg/ml. In rats, micro-injection of GF109203X into the NTS at 0.08 μg/side inhibits Ang II-induced inhibition of baroreflex gain (34) . Considering the production rate and total volume of CSF in rats, we estimated that the dose for acute icv administration needs to be at least 0.2 μg to inhibit PKC in the brain. Two groups (n=8/group) of Wistar rats on regular salt were instrumented with an icv guide cannula, and an intra-arterial catheter in the femoral artery 5 days later. About 18 h after arterial cannulation, BP and HR were recorded for 10 min in resting rats, and via a stainless steel needle Na 
Effects of chronic icv infusion of staurosporine in Dahl rats.
In 2 groups of Dahl S rats and 2 groups of SS.BN13 rats (n=7-8/ group) under isoflurane anesthesia, an L-shaped, 23 gauge stainless steel cannula was placed into the right lateral cerebro-ventricle (14) . Via polyethylene tubing the other end of the cannula was connected to an osmotic minipump (Alzet, Model 2002, rate: 0.5μl/h) placed subcutaneously (sc) for icv infusion of either staurosporine (Sigma Chemical Co.) at 25 ng/day or vehicle [artificial CSF (aCSF) with 0.5% ethanol]. In our previous studies, icv infusion of aCSF with 1-2% ethanol at the same rate had no effects on resting hemodynamics or behaviour (37) . The rate for icv infusion of staurosporine was estimated from in vitro studies and the total volume and production rate of CSF.
Considering that the CSF production rate is about ~6 ml/d and total CSF volume is ~0.5 ml in rats of ~300 g body weight. At the end of the 2-week icv infusion and high salt intake, under isoflurane anesthesia a PE catheter (PE10 fused to PE50) was placed into the right femoral artery. The catheter was filled with heparinized saline and exteriorized on the back of each rat. The next morning about 18 hour after the arterial cannulation, the arterial line was connected to a pressure transducer, Grass polygraph and tachograph. After a rest of about 30 min, BP and HR were recorded for 5 minutes. The average BP and HR recorded over these 5 min was used as the resting BP and HR. The rat was then re-anesthetized with isoflurane and 100-200µl CSF was collected from the cisterna magna at <10µl/sec (14) . After decapitation, the whole brain was removed, frozen quickly in dry ice and stored at -80°C.
The whole hypothalamus and hippocampus were dissected according to Glowinski and Iversen (8) .
The accuracy of the placement of the icv cannulae were verified by either injection of blue dye after the short-term study or by visual examination during tissue collection in the chronic study. A few rats (3 out of 61) with unsuccessful icv cannulation in the acute experiments were excluded.
SIK1 protein and activity in the hypothalamus.
SIK1 activity was measured in immuno-purified hypothalamic tissue, using [γ- To assess the in vitro inhibition of SIK1 by staurosporine, SIK1 activity was compared in replicate aliquots of the immunopurified tissue preparations to which staurosporine was added in final concentrations of 0, 5, 25 or 50 nM (determined from initial experiments with active SIK1, Signal Chem #S14-11H-05). The activity in the samples with added staurosporine was expressed as a % of that in the same sample without the inhibitor.
In a separate experiment, the identity of the proteins in the immunoprecipitate were confirmed by SDS-PAGE using a 10% Bis-Acrylamide gel. Proteins were transblotted onto a PVDF membrane which was subsequently blocked with 5% milk , incubated at 
Aldosterone and corticosterone in hypothalamus and hippocampus
Aldosterone was measured by radioimmunoassay (RIA) after tissue preparation and SepPak extraction as described previously (25) (12) , and 17 pg/g in the hippocampus.
All samples from the experiment were done in one assay, with an intra-assay variation of 7%. Cross re-activities were 0.03 and 0.14 % for corticosterone and DOC, respectively. 
Results
Hypothalamic SIK1 protein and activity, and inhibition by staurosporine.
For SIK1 protein, both bands were significantly lower by 20-30% in the hypothalamus of the Dahl S ras compared to the SS.BN13 controls (Fig 1) . SIK1 activity in the hypothalamus followed the same pattern (Fig 1) . Staurosporine at 5, 25 and 50 nM inhibited hypothalamic SIK1 activity by 50-80% in a dose-related manner in both SS.BN13 and S rats (Fig 2) . The in vitro % inhibition by staurosporine at corresponding concentrations was somewhat more pronounced in the S rats (p=0.04).
Icv staurosporine and responses to acute increases in CSF [
Among Wistar, SS.BN13 and S rats on regular salt, there were no significant differences in resting MAP (109±4, 107±3, and 114±4 mmHg), HR (398±14, 387±12, and 409±10 bpm) and RSNA (6.7±2.2, 5.6±2.0 and 7.7±2.1 mV). MAP, HR and RSNA started to increase within 1-2 min after the start of icv infusion of Na + -rich aCSF, reached a plateau within 3-4 min, and returned to basal levels within 2-3 min after the termination of icv infusion (Fig 3 and 4) .This pattern was similar in Wistar and SS.BN13 and S rats, except that the maximal responses were significantly larger in Dahl S rats (Table 1, Fig 3) .
No changes in resting MAP, HR and RSNA were observed during the 3 min after icv injection of vehicle or staurosporine (data not shown). Na + -rich aCSF -induced increases in MAP, HR and RSNA were not affected by icv vehicle in all 3 strains (Fig 2, 3) . In contrast, after icv staurosporine the maximal increases in MAP, HR and RSNA induced by icv infusion of Na + -rich aCSF were significantly larger compared to those before staurosporine ( Table 1, Fig 3 and 4) . Whereas the absolute differences between maximal BP responses after versus before staurosporine were similar in the 3 strains, the differences of RSNA and HR responses were significantly smaller in Dahl S versus SS.BN13 or Wistar rats ( Table 1 ). The % increases in the maximal responses of MAP, RSNA and HR to staurosporine were similar in SS.BN13 and Wistar rats, and for all 3 parameters significantly larger than in Dahl S rats (Table 1) . However, the maximal responses to icv infusion of Na + -rich aCSF remained significantly larger after staurosporine in Dahl S rats versus SS.BN13 or Wistar rats (Table 1 ).
Compared to icv infusion of aCSF, icv infusion of Na 
Icv staurosporine and responses to icv Ang II and carbachol
As shown in Table 2 , icv injection of Ang II increased BP and HR in a dose-related manner, and icv injection of staurosporine did not affect these responses. Icv injection of carbachol increased BP and decreased HR in a dose-related fashion, and these responses were also not affected by staurosporine.
Effects of GF109203X on responses to icv Na
+ -rich aCSF and Ang II.
No changes in resting MAP and HR were observed during the 3 min after icv injection of vehicle or GF109203X. Na + -rich aCSF or Ang II -induced increases in MAP were similar before and after icv vehicle (Fig 5) . In contrast, after icv GF109203X the increases in MAP by Na + -rich aCSF or Ang II were significantly attenuated by 50-70% compared to those after injection of vehicle or before icv GF109203X.
Chronic icv infusion of staurosporine in Dahl rats on high salt.
There were no significant differences in initial body weight or weight gain among the 4 groups of rats on high salt, treated with either icv vehicle or staurosporine for 2 weeks (228±12 and 210±9 g or +58±3 and +61±4 g for Dahl S and SS.BN13 rats with vehicle, and 225±13 and 208±13 or +59±4 and +63±3 g for Dahl S and SS.BN13 rats with staurosporine).
After 2 weeks of high salt intake, resting MAP was significantly higher in Dahl S versus SS.BN13 rats treated with icv infusion of vehicle (Fig 6) . In SS.BN13 rats, MAP was not affected by icv infusion of staurosporine. In contrast, in Dahl S rats icv infusion of staurosporine further increased MAP significantly by ~15 mmHg. Resting HR tended (p=0.07) to be higher in Dahl S versus SS.BN13 rats treated with icv infusion of vehicle, and was significantly higher in Dahl S rats with icv infusion of staurosporine. Compared with SS.BN13 rats, Dahl S rats on high salt showed significantly higher aldosterone levels in both the hypothalamus and hippocampus. Corticosterone levels were only increased in the hypothalamus (Fig 7) . These increases persisted in Dahl S rats treated with icv infusion of staurosporine (Fig 7) .
Discussion
The present study shows that: 1) SIK1 protein and activity are significantly lower in the hypothalamus of Dahl S versus SS.BN13 rats; 2) icv injection of staurosporine significantly enhances excitatory RSNA, BP, and HR responses to icv infusion of Na 
Limitations
There are some limitations to consider. Firstly, icv infusion and whole hypothalamus assays do not provide insights into the central pathways/nuclei where SIK1 is operative.
Local injections of staurosporine and assays in punches of nuclei may be useful in this regard. Secondly, food (and salt) intake were not measured and an increase in BP could result from increased salt and water consumption by staurosporine. However, the gain of body weight, visible food intake on high salt diet and CSF [Na + ] were similar in Dahl S rats on high salt with and without icv infusion of staurosporine, and no behavioral changes were observed in staurosporine-treated rats. It appears unlikely that staurosporine itself further increased salt intake and thereby increased BP. Thirdly, BP and HR were measured through an arterial catheter 18 h after cannulation and a 30 min rest. These are not as ideal as data obtained by telemetry, and likely overestimate resting values somewhat.
Perspectives and significances
The present study provides new insights into intra-neuronal mechanisms regulating neuronal responses to CSF Na Between strains (see also Data are mean±SE (n=8/group) and compared with student t-test. * p<0.05, vs. after icv vehicle. For comparisons of maximal responses between strains either before or after staurosporine:
for BP, F=68.1 (p=0.0001); for RSNA, F=25.5 (p=0.0002); for HR, F=30.1 (p=0.0002).
For comparisons of maximal responses before and after staurosporine in all strains:
for BP, F=40.1 (p=0.0001); for RSNA, F=49.9 (p=0.0001); for HR, F=31.9 (p=0.0001).
For comparisons of absolute increases in responses:
for BP, F=0.58 (p=0.56); for RSNA, F=16.0 (p=0.0001); for HR, F=22.5 (p=0.0001).
For comparisons of % increases in responses:
for BP, F=51. 
